X Square Capital LLC Sells 7,825 Shares of OPKO Health, Inc. (NASDAQ:OPK)

X Square Capital LLC decreased its position in OPKO Health, Inc. (NASDAQ:OPK) by 4.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 161,726 shares of the biotechnology company’s stock after selling 7,825 shares during the quarter. X Square Capital LLC’s holdings in OPKO Health were worth $238,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of OPK. FMR LLC lifted its stake in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 11,089 shares during the period. Orion Portfolio Solutions LLC bought a new stake in OPKO Health during the third quarter valued at $45,000. Cibc World Markets Corp bought a new stake in OPKO Health in the 4th quarter worth approximately $45,000. Ieq Capital LLC purchased a new stake in OPKO Health during the 4th quarter valued at $52,000. Finally, World Investment Advisors LLC bought a new stake in shares of OPKO Health during the 3rd quarter valued at about $61,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.74 on Friday. OPKO Health, Inc. has a twelve month low of $1.12 and a twelve month high of $2.04. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The stock has a fifty day simple moving average of $1.68 and a 200-day simple moving average of $1.58. The stock has a market cap of $1.17 billion, a PE ratio of -9.16 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Equities analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on OPK shares. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, March 19th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Wednesday, March 12th.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 47,537 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was bought at an average cost of $1.47 per share, for a total transaction of $69,879.39. Following the completion of the acquisition, the chief executive officer now directly owns 213,234,014 shares in the company, valued at $313,454,000.58. This represents a 0.02 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders bought 964,971 shares of company stock valued at $1,493,692 over the last 90 days. 47.26% of the stock is owned by corporate insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.